MIN 102Alternative Names: MIN-102
Latest Information Update: 04 Jan 2017
At a glance
- Originator IDIBELL
- Developer Minoryx Therapeutics
- Class Small molecules; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Adrenoleucodystrophy